SCHEMBL19686404

SCHEMBL19686404

COC(=O)NCc1cc(NC2CCC(F)(F)CC2)nc(-n2ccc(CF)n2)c1

nearest known ligand 0.34

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IDH1 O75874 4/20 0.34
P2RX7 Q99572 3/20 0.33
F2 P00734 1/20 0.32
F11 P03951 1/20 0.32
SCN9A Q15858 1/20 0.32
NAPEPLD Q6IQ20 2/20 0.32
METTL3 Q86U44 1/20 0.32
PDE2A O00408 1/20 0.31
PRKAB2 O43741 1/20 0.31
PRKAG1 P54619 1/20 0.31
PRKAA2 P54646 1/20 0.31
PRKAA1 Q13131 1/20 0.31
PRKAG3 Q9UGI9 1/20 0.31
PRKAG2 Q9UGJ0 1/20 0.31
PRKAB1 Q9Y478 1/20 0.31
TSHR P16473 1/20 0.30
CNR1 P21554 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21166293 0.94 IDH1 (0.34) IDH1P2RX7F2F11NAPEPLD
SCHEMBL19686343 0.91 IDH1 (0.35) IDH1P2RX7F2F11SCN9A
SCHEMBL21143958 0.90 IDH1 (0.35) IDH1P2RX7F2F11NAPEPLD
SCHEMBL19686925 0.90 IDH1 (0.34) IDH1P2RX7F2F11NAPEPLD
SCHEMBL19686409 0.90 PDE2A (0.35) IDH1P2RX7F2F11NAPEPLD
SCHEMBL21144021 0.85 CCNA2 (0.36) IDH1F2F11NAPEPLDMETTL3
SCHEMBL21143754 0.84 IDH1 (0.36) IDH1P2RX7F2F11NAPEPLD
SCHEMBL21143975 0.83 IDH1 (0.34) IDH1F2F11NAPEPLDMETTL3
SCHEMBL31127100 0.83 IDH1 (0.34) IDH1F2F11NAPEPLDMETTL3
SCHEMBL21144273 0.82 IDH1 (0.32) IDH1F2F11NAPEPLDMETTL3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2024-09-26 US disclosed
US-10774064-B2 Potassium channel modulators CADENT THERAPEUTICS, INC. (US) 2020-09-15 US disclosed
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS NOVARTIS AG (CH) 2019-07-18 US disclosed
WO-2017139697-A9 BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH HYPERAMMONEMIA SYNLOGIC, INC. (US) 2017-12-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240317705-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885P2RX7 271/4885F2 4167/4885
US-10774064-B2 Potassium channel modulators KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885P2RX7 271/4885F2 4167/4885
US-20190218200-A1 POTASSIUM CHANNEL MODULATORS KCNJ11, KCNJ2, KCNJ1 IDH1 3017/4885P2RX7 271/4885F2 4167/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.